Clik here to view.
Allergan settles Restasis patent challenge after moving patents to Native...
Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis. InnoPharma is one of four companies challenging Allergan’s...
View ArticleClik here to view.
Nasdaq halts trading of Aerie stock as FDA reviews Rhopressa NDA
Aerie Pharmaceuticals (NSDQ:AERI) said today that Nasdaq has halted trading of the company’s common stock as an FDA committee convenes to review Aerie’s new drug application for its Rhopressa glaucoma...
View ArticleClik here to view.
Tandem prices $16m public offering
Tandem Diabetes Care (NSDQ:TNDM) today priced an underwritten public offering of 4,630,000 shares of its common stock, Series A warrants and Series B warrants to buy 4,630,000 shares of common stock at...
View ArticleClik here to view.
Ethics watchdog: Rep. Collins broke rules by advocating for biotech
There’s “substantial reason to believe” that Rep. Chris Collins (R-NY) broke federal law and congressional rules by sharing insider information to spur investment and by meeting with government...
View ArticleClik here to view.
Milestone Scientific names interim chief executive | Personnel Moves – Oct....
Milestone Scientific (NYSE:MLSS) said last week that chairman of the board Leslie Bernhard will take over as interim CEO after former president & CEO Daniel Goldberger resigned at the start of this...
View ArticleClik here to view.
Propeller Health launches API to provide local asthma conditions to orgs,...
Earlier this week, Propeller Health released an application programming interface to give local asthma conditions to anyone within the U.S. who is interested in using that data. The Air by Propeller...
View ArticleClik here to view.
FDA advisory committee backs Aerie’s Rhopressa eye drug
An FDA advisory committee voted today in favor of Aerie Pharmaceuticals‘ (NSDQ:AERI) Rhopressa product candidate. The dermatologic and ophthalmic drugs advisory committee voted unanimously that...
View ArticleClik here to view.
CDC: Overdose-related deaths in 2016 surpassed death count from peak of AIDS...
More than 63,000 people died from a drug overdose last year – that’s more than the number of deaths caused by AIDS in 1995, according to data from the Centers for Disease Control and Prevention....
View ArticleClik here to view.
Reva Medical launches Fantom in Switzerland with first implant of...
Reva Medical (ASX:RVA) has expanded its commercial operations into Switzerland, the company said today, with the first implant of its Fantom bioresorbable scaffold. The scaffold is made from Reva’s...
View ArticleClik here to view.
Insulet shareholder sues over OmniPod Eros
Insulet (NSDQ:PODD) shareholder Frank Carnazza filed a derivative suit against the Billerica, Mass-based company last week in a Massachusetts federal court, alleging that Insulet misrepresented the...
View ArticleClik here to view.
NanOlogy takes nanoparticle tech into Phase II trials
In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with prostate cancer and in patients with ovarian cancer. The...
View ArticleClik here to view.
Texas judge rules Allergan’s Restasis patents invalid
U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon...
View ArticleClik here to view.
Mylan: Allergan’s legal move with tribe reveals “duplicitousness” towards...
Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the...
View ArticleClik here to view.
Researchers combine a smart phone, insulin pump and CGM in diabetes study
In a study published this week in Diabetes Care, researchers combined an insulin pump, a continuous glucose monitoring receiver and a smart phone with cloud-based algorithms to automatically monitor...
View ArticleClik here to view.
Adventist Health System to use Glytec’s diabetes management system at 39...
Glytec has partnered with Adventist Health System to bring its eGlycemic diabetes management system to 39 of the health system’s acute care facilities. Glytec’s cloud-based eGMS will become a part of...
View ArticleClik here to view.
Anika’s Monovisc therapy gets green light in Australia
Anika Therapeutics (NSDQ:ANIK) said yesterday that regulatory authorities in Australia approved the company’s single injection viscosupplement, Monovisc, for the treatment of pain associated with...
View ArticleClik here to view.
How etectRx’s “smart pill” aims to improve patient compliance trends
When Harry Travis first met Neil Euliano and learned about his medication adherence technology, the pharmaceutical industry was beginning to usher in the age of pricey drugs with Hepatitis C therapies...
View ArticleClik here to view.
Amgen, Boston Children’s Hospital partner to find genes linked to pain disorders
Amgen (NSDQ:AMGN) announced today that it inked a one-year collaboration with Boston Children’s Hospital to study patients with pain syndromes in an effort to identify potential genetic targets. The...
View ArticleClik here to view.
UK design firm touts new device as “the Nespresso of auto-injectors”
People living with chronic diseases often have to treat themselves at home using a medical device like an auto-injector. The process can be nerve-wracking, because it requires the patient to follow a...
View ArticleClik here to view.
FDA committee backs Novo Nordisk’s once-weekly type II diabetes drug
An FDA advisory committee has voted favorably to approve Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide Type II diabetes drug. Shares in the insulin maker were up 2% in after-hours activity today,...
View Article